-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
PSI-6130
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/817204-33-4.gif)
| Category | HCV Protease |
| CAS | 817204-33-4 |
| Description | PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes. |
Product Information
| Synonyms | 2'-deoxy-2'-Fluoro-2'-methylcytidine; R 1656; R-1656; R1656; 2'-F-2'-Me-dC; 2'-Deoxy-2'-fluoro-2'-C-methylcytidine; PSI 6130; 4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro-2-methyl-β-D-ribofuranosyl)- |
| IUPAC Name | 4-amino-1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one |
| Molecular Weight | 259.23 |
| Molecular Formula | C10H14FN3O4 |
| Canonical SMILES | CC1(C(C(OC1N2C=CC(=NC2=O)N)CO)O)F |
| InChI | InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1 |
| InChIKey | NYPIRLYMDJMKGW-VPCXQMTMSA-N |
| Boiling Point | 482.4±55.0°C (Predicted) |
| Melting Point | >162°C (dec.) |
| Flash Point | 245.5±31.5 °C |
| Purity | ≥97% by HPLC |
| Density | 1.67±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in Methanol (Slightly), Water (Slightly) |
| Appearance | White to Light Brown Solid |
| Storage | Store at -20°C under inert atmosphere |
| Complexity | 427 |
| Exact Mass | 259.09683410 |
| Index Of Refraction | 1.653 |
| In Vitro | PSI-6130 exhibits potent and specific inhibitory activity against HCV RNA replication mediated by the NS5B polymerase. Both PSI-6130 inhibit HCV GT-1b (Con1 strain) and GT-1a (H77 strain) subgenomic RNA replication, with mean EC50 values of 0.51 and 0.30 μM, respectively. PSI-6130 inhibits 40% human serum with EC50 of 0.51 μM. PSI-6130 inhibits HCV replication with a mean IC50 of 0.6 μM, PSI-6130-TP inhibits HCV replicase with a mean IC50 of 0.34 μM. PSI-6130-TP inhibits recombinant HCV Con1 NS5B on a heteropolymeric RNA template derived from the 3'-end of the negative strand of the HCV genome with an IC50 of 0.13 μM and Ki of 0.023 μM. |
| PSA | 110.60000 |
| Target | IC50: 0.6 μM (HCV replication) |
| Vapor Pressure | 0.0±2.7 mmHg at 25°C |
| XLogP3-AA | -1.4 |
